Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Precision Biosciences (DTIL) Change in Cash (2018 - 2025)

Historic Change in Cash for Precision Biosciences (DTIL) over the last 8 years, with Q3 2025 value amounting to -$13.6 million.

  • Precision Biosciences' Change in Cash fell 50606.33% to -$13.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$50.1 million, marking a year-over-year decrease of 544994.46%. This contributed to the annual value of -$8.2 million for FY2024, which is 8873.77% up from last year.
  • As of Q3 2025, Precision Biosciences' Change in Cash stood at -$13.6 million, which was down 50606.33% from -$15.0 million recorded in Q2 2025.
  • Over the past 5 years, Precision Biosciences' Change in Cash peaked at $103.7 million during Q1 2021, and registered a low of -$31.4 million during Q1 2023.
  • Moreover, its 5-year median value for Change in Cash was -$13.6 million (2025), whereas its average is -$978210.5.
  • Per our database at Business Quant, Precision Biosciences' Change in Cash surged by 48826.17% in 2021 and then plummeted by 50606.33% in 2025.
  • Quarter analysis of 5 years shows Precision Biosciences' Change in Cash stood at -$16.8 million in 2021, then plummeted by 33.72% to -$22.5 million in 2022, then soared by 75.29% to -$5.6 million in 2023, then tumbled by 131.59% to -$12.9 million in 2024, then decreased by 5.71% to -$13.6 million in 2025.
  • Its Change in Cash stands at -$13.6 million for Q3 2025, versus -$15.0 million for Q2 2025 and -$8.7 million for Q1 2025.